Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Cipla
Baxter
UBS
Julphar
Novartis
Deloitte
Federal Trade Commission
Dow
Moodys
Colorcon

Generated: August 19, 2017

DrugPatentWatch Database Preview

BREVIBLOC Drug Profile

« Back to Dashboard

What is the patent landscape for Brevibloc, and when can generic versions of Brevibloc launch?

Brevibloc is a drug marketed by Baxter Hlthcare and is included in one NDA. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has thirty-three patent family members in twenty-four countries.

The generic ingredient in BREVIBLOC is esmolol hydrochloride. There are eight drug master file entries for this compound. Ten suppliers are listed for this compound. Additional details are available on the esmolol hydrochloride profile page.

Summary for Tradename: BREVIBLOC

Patents:2
Applicants:1
NDAs:1
Suppliers / Packagers: see list4
Bulk Api Vendors: see list50
Clinical Trials: see list12
Patent Applications: see list524
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:BREVIBLOC at DailyMed

Pharmacology for Tradename: BREVIBLOC

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Baxter Hlthcare
BREVIBLOC
esmolol hydrochloride
INJECTABLE;INJECTION019386-003Aug 15, 1988DISCNNoNo► Subscribe► Subscribe► Subscribe
Baxter Hlthcare
BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER
esmolol hydrochloride
INJECTABLE;INJECTION019386-005Jan 27, 2003RXYesYes► Subscribe► SubscribeY► Subscribe
Baxter Hlthcare
BREVIBLOC
esmolol hydrochloride
INJECTABLE;INJECTION019386-007May 28, 2003DISCNNoNo► Subscribe► SubscribeY► Subscribe
Baxter Hlthcare
BREVIBLOC IN PLASTIC CONTAINER
esmolol hydrochloride
INJECTABLE;INJECTION019386-004Feb 16, 2001RXYesYes► Subscribe► SubscribeY► Subscribe
Baxter Hlthcare
BREVIBLOC
esmolol hydrochloride
INJECTABLE;INJECTION019386-006Feb 25, 2003APRXYesYes► Subscribe► SubscribeY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: BREVIBLOC

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Baxter Hlthcare
BREVIBLOC
esmolol hydrochloride
INJECTABLE;INJECTION019386-007May 28, 2003► Subscribe► Subscribe
Baxter Hlthcare
BREVIBLOC
esmolol hydrochloride
INJECTABLE;INJECTION019386-003Aug 15, 1988► Subscribe► Subscribe
Baxter Hlthcare
BREVIBLOC
esmolol hydrochloride
INJECTABLE;INJECTION019386-003Aug 15, 1988► Subscribe► Subscribe
Baxter Hlthcare
BREVIBLOC
esmolol hydrochloride
INJECTABLE;INJECTION019386-003Aug 15, 1988► Subscribe► Subscribe
Baxter Hlthcare
BREVIBLOC
esmolol hydrochloride
INJECTABLE;INJECTION019386-006Feb 25, 2003► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: BREVIBLOC

Drugname Dosage Strength RLD Submissiondate
esmolol hydrochlorideInjection10 mg/mL, 250 mL infusion bags and 20 mg/mL, 100 mL infusion bagsBrevibloc1/31/2014

International Patent Family for Tradename: BREVIBLOC

Country Document Number Estimated Expiration
Argentina035416► Subscribe
European Patent Office1368019► Subscribe
Japan2004519506► Subscribe
Japan2010024249► Subscribe
China1981739► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Mallinckrodt
Cantor Fitzgerald
Accenture
Teva
Federal Trade Commission
Cipla
Argus Health
McKinsey
Chinese Patent Office
US Army

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot